NCT02238626View on ClinicalTrials.gov

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Placebo (for MN-166)

DRUG

MN-166

DRUG

riluzole

Patient is given 50 mg riluzole twice daily.

Trial Locations (1)

28232-2861

Carolinas Healthcare System, Dept. of Neurology, Charlotte

Sponsors

Lead Sponsor

MediciNova
All Listed Sponsors
collaborator

Wake Forest University Health Sciences

OTHER

lead

MediciNova

INDUSTRY

NCT02238626 - Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter